Kelun-Biotech returns to profit with FY26 H1 net income RMB 388.01 million; revenue rises 2.9% to RMB 978.34 million

• Sichuan Kelun-Biotech posted a profit attributable to shareholders of RMB 388.01 million, returning to profit from a loss a year earlier.
• Revenue rose 2.9% to RMB 978.34 million, while operating profit turned positive at RMB 250.03 million.
• R&D expenses increased 25.7% to RMB 768.43 million, while selling and distribution costs more than doubled to RMB 390.6 million.
• Other net income climbed to RMB 752.06 million, driven by RMB 702.72 million of settlement income.
• Commercial product sales more than doubled to RMB 657.04 million; cash and financial assets increased 4.9% to RMB 4.78 billion.

Disclaimer: This news brief was created by Public Technologies (PUBT) using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Sichuan Kelun-Biotech Biopharmaceutical Co., Ltd. published the original content used to generate this news brief via IIS, the regulatory disclosure system operated by the Hong Kong Stock Exchange (HKex) (Ref. ID: HKEX-EPS-20260817-12287215), on August 17, 2026, and is solely responsible for the information contained therein.